Gene silencing of NOB1 by lentivirus suppresses growth and migration of human osteosarcoma cells Corrigendum in /10.3892/mmr.2022.12909

Chen,Bingpeng; Liu,Jingjing; Wu,Dankai; Qin,Yanguo; Peng,Chuangang; Li,Chen; Wang,Jincheng

doi:10.3892/mmr.2014.2119

Gene silencing of NOB1 by lentivirus suppresses growth and migration of human osteosarcoma cells

Corrigendum in: /10.3892/mmr.2022.12909

Authors:
- Bingpeng Chen
- Jingjing Liu
- Dankai Wu
- Yanguo Qin
- Chuangang Peng
- Chen Li
- Jincheng Wang
View Affiliations

Affiliations: Department of Orthopedics, The Second Hospital of Jilin University, Changchun, Jilin 130041, P.R. China, Department of Oncology, Jilin Tumor Hospital, Changchun, Jilin 130021, P.R. China
Published online on: April 4, 2014 https://doi.org/10.3892/mmr.2014.2119
Pages: 2173-2179
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

NIN1/RPN12 binding protein 1 homolog (Saccharomyces cerevisiae) (NOB1) encodes a chaperone protein that joins the 20S proteasome with the 19S regulatory particle in the nucleus and facilitates the biogenesis of the 26S proteasome, which plays a role in maintaining cellular homeostasis by controlling protein degradation. In order to investigate the role of NOB1 in osteosarcoma, NOB1 protein expression in human osteosarcoma cell lines was assessed using western blot analysis. Lentivirus‑mediated short hairpin RNA was employed to knock down NOB1, and the effects of NOB1 silencing on cell growth were assessed using MTT, colony formation and cell cycle assays. Cell migration was observed using the Transwell assay. In addition, the expression levels of E‑cadherin and β‑catenin were examined by western blot analysis. Functional analysis indicated that NOB1‑knockdown markedly inhibited cell growth and caused G2/M‑phase arrest in human osteosarcoma cells. Furthermore, NOB1 inhibition decreased cell migration and increased E‑cadherin and β‑catenin expression in U2OS cells. In conclusion, the present study suggested that NOB1 depletion may inhibit osteosarcoma development by increasing E‑cadherin and β‑catenin expression and, for the first time, indicated the potential of NOB1 as a target in osteosarcoma treatment.

View Figures

View References

1	Glickman MH and Ciechanover A: The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev. 82:373–428. 2002.PubMed/NCBI
2	Ferrell K, Wilkinson CR, Dubiel W and Gordon C: Regulatory subunit interactions of the 26S proteasome, a complex problem. Trends Biochem Sci. 25:83–88. 2000. View Article : Google Scholar : PubMed/NCBI
3	Frezza M, Schmit S and Dou QP: Targeting the ubiquitin-proteasome pathway: an emerging concept in cancer therapy. Curr Top Med Chem. 11:2888–2905. 2011. View Article : Google Scholar : PubMed/NCBI
4	Yerlikaya A and Yöntem M: The significance of ubiquitin proteasome pathway in cancer development. Recent Pat Anticancer Drug Discov. 8:298–309. 2013. View Article : Google Scholar : PubMed/NCBI
5	Pandit B and Gartel AL: Thiazole antibiotic thiostrepton synergize with bortezomib to induce apoptosis in cancer cells. PLoS One. 6:e171102011. View Article : Google Scholar : PubMed/NCBI
6	Piperdi B, Ling YH, Liebes L, Muggia F and Perez-Soler R: Bortezomib: understanding the mechanism of action. Mol Cancer Ther. 10:2029–2030. 2011. View Article : Google Scholar : PubMed/NCBI
7	Dick LR and Fleming PE: Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today. 15:243–249. 2010. View Article : Google Scholar : PubMed/NCBI
8	Shapovalov Y, Benavidez D, Zuch D and Eliseev RA: Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma. Int J Cancer. 127:67–76. 2010. View Article : Google Scholar : PubMed/NCBI
9	Pandit B, Bhat UG and Gartel AL: Proteasome inhibitory activity of thiazole antibiotics. Cancer Biol Ther. 11:43–47. 2011. View Article : Google Scholar : PubMed/NCBI
10	Bhat UG, Zipfel PA, Tyler DS and Gartel AL: Novel anticancer compounds induce apoptosis in melanoma cells. Cell Cycle. 7:1851–1855. 2008. View Article : Google Scholar : PubMed/NCBI
11	Tone Y, Tanahashi N, Tanaka K, Fujimuro M, Yokosawa H and Toh-e A: Nob1p, a new essential protein, associates with the 26S proteasome of growing Saccharomyces cerevisiae cells. Gene. 243:37–45. 2000. View Article : Google Scholar : PubMed/NCBI
12	Tone Y and Toh-E A: Nob1p is required for biogenesis of the 26S proteasome and degraded upon its maturation in Saccharomyces cerevisiae. Genes Dev. 16:3142–3157. 2002. View Article : Google Scholar : PubMed/NCBI
13	Oehler VG, Yeung KY, Choi YE, Bumgarner RE, Raftery AE and Radich JP: The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data. Blood. 114:3292–3298. 2009. View Article : Google Scholar : PubMed/NCBI
14	Lu Z, Guo Q, Shi A, Xie F and Lu Q: Downregulation of NIN/RPN12 binding protein inhibit the growth of human hepatocellular carcinoma cells. Mol Biol Rep. 39:501–507. 2012. View Article : Google Scholar : PubMed/NCBI
15	Lin Y, Peng S, Yu H, Teng H and Cui M: RNAi-mediated downregulation of Nob1 suppresses the growth and colony-formation ability of human ovarian cancer cells. Med Oncol. 29:311–317. 2012. View Article : Google Scholar : PubMed/NCBI
16	Sakoda T, Kasahara N, Hamamori Y and Kedes L: A high-titer lentiviral production system mediates efficient transduction of differentiated cells including beating cardiac myocytes. J Mol Cell Cardiol. 31:2037–2047. 1999. View Article : Google Scholar
17	Soneoka Y, Cannon PM, Ramsdale EE, et al: A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res. 23:628–633. 1995. View Article : Google Scholar : PubMed/NCBI
18	Pfaffl MW, Horgan GW and Dempfle L: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 30:e362002. View Article : Google Scholar : PubMed/NCBI
19	Adams BK, Ferstl EM, Davis MC, et al: Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg Med Chem. 12:3871–3883. 2004. View Article : Google Scholar : PubMed/NCBI
20	Lee SJ, Choi SY, Kim WJ, et al: Combined aberrant expression of E-cadherin and S100A4, but not β-catenin is associated with disease-free survival and overall survival in colorectal cancer patients. Diagn Pathol. 8:992013.
21	Onder TT, Gupta PB, Mani SA, Yang J, Lander ES and Weinberg RA: Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 68:3645–3654. 2008. View Article : Google Scholar : PubMed/NCBI
22	Perl AK, Wilgenbus P, Dahl U, Semb H and Christofori G: A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature. 392:190–193. 1998. View Article : Google Scholar : PubMed/NCBI
23	Derksen PW, Liu X, Saridin F, et al: Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell. 10:437–449. 2006. View Article : Google Scholar : PubMed/NCBI
24	Debald M, Kaiser C, Abramian A, et al: Evaluation of E-cadherin, Ki-67 and lymphatic vessel invasion in abdominal metastases of human breast cancer. Anticancer Res. 33:1971–1975. 2013.PubMed/NCBI
25	Cai Y, Mohseny AB, Karperien M, Hogendoorn PC, Zhou G and Cleton-Jansen AM: Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol. 220:24–33. 2010. View Article : Google Scholar : PubMed/NCBI